Ms. McAuley most recently served as chief operating officer of Integrium, a therapeutically-focused, full-service CRO. Previously, she was senior director of Clinical Operations for Alteon, a biotechnology company focused on development of novel treatments for cardiovascular diseases.
“We are delighted to welcome Eileen McAuley to our senior leadership team at Frontage. She has exceptional skills in developing sustainable organizational growth, and can offer our clients guidance to effectively manage clinical research programs across multiple therapeutic areas,” said Carlos Orantes, chief operating officer of Frontage Labs. “Ms. McAuley’s leadership abilities and experience will enable Frontage to enhance our service offerings and the overall value we deliver to our clients as we keep pace with the growing complexity of clinical development.”
Additionally, Frontage plans to expand its clinical research operations with a new 33,000 sq.-ft. clinical research center in Secaucus, NJ, scheduled to open late in 2014. The new facility will include enhancements to conduct a wider range of clinical studies, as well as multiple, concurrent studies, and will nearly triple the company’s clinical capacity in the U.S.
“By expanding our investment and infrastructure in clinical services, Frontage will be well-positioned to comprehensively support the early development needs of our clients,” said Song Li, chief executive officer of Frontage.